Two additional world-renowned oncologists will join NuProbe’s clinical advisory board: Amir A. Jazaeri, M.D., from the University of Texas MD Anderson Cancer Center and Abhijit Patel, M.D., Ph.D., from Yale University School of Medicine
NuProbe and QIAGEN will collaborate to develop next-generation sequencing (NGS)-based cancer diagnostic tests for non-invasive liquid biopsy. NuProbe and QIAGEN will explore integrating their two amplicon-based enrichment and sequencing technologies: NuProbe’s proprietary Blocker Displacement Amplification (BDA) technology and QIAGEN’s Single Primer Extension (SPE) technology,
Oxford Nanopore has licensed NuProbe’s Blocker Displacement Amplification technology globally for undisclosed consideration. The technology combination offers the potential to combine Oxford Nanopore sequencing, which offers real-time, rapid turnaround, scalable sequencing of any length DNA or RNA fragments, with the NuProbe technique to enable greater detection sensitivities and quantification of somatic mutations at less than 5% allele frequency.
NuProbe Global and CarrierGene Biotech Co. Ltd. (Suzhou, China) announced the successful completion of their recent merger and integration. The new company will operate under the English brand NuProbe Global and the Chinese brand阅尔 (Yue Er).
NuProbe Global launches VarTrace™ product line of Sanger assays for ultrasensitive detection and quantification of cancer mutations with variant allele frequencies (VAF) down to 0.1%.
George M. Church, Ph.D., Professor of Genetics at Harvard Medical School, and David R. Walt, Ph.D., Professor of Pathology at Harvard Medical School will form NuProbe’s Scientific Advisory Board.
NuProbe raised $11 million to continue development of ultra-sensitive, non-invasive blood test for the early detection of cancer and infectious diseases. The Series A funding was co-led by Sequoia China and Serica Partners.